Tag
Pharma / Healthcare
89 articles
The Indian pharmaceutical sector is navigating a mixed regulatory landscape and demonstrating varied operational developments. Cipla faces a Directorate of Revenue Intelligence search regarding import classification, while its InvaGen subsidiary received a No Action Indicated classification from the USFDA, signaling compliance. Elsewhere, Senores Pharmaceuticals secured PIC/S GMP certification, expanding its regulatory pathway, and Glenmark’s IGI subsidiary submitted an IND application for a novel cancer drug, ISB 2301. These developments, alongside shareholder approvals for director appointments at Bliss GVS Pharma and AstraZeneca, highlight the sector’s ongoing focus on regulatory adherence, innovation, and governance, though Cipla’s DRI investigation introduces a degree of uncertainty.
Cipla's InvaGen USFDA Inspection Gets NAI Classification
Cipla discloses USFDA classified its InvaGen subsidiary's Hauppauge facility inspection as No Action Indicated (NAI).
The inspection occurred from 19-22 October 2026, with the NAI classification commu
Senores Subsidiary Ratnatris Receives PIC/S GMP Certification
Senores Pharmaceuticals subsidiary Ratnatris receives PIC/S GMP certification from Ukraine's State Service of Medicines and Drugs Control.
Certification issued on November 16, 2026, and received by th
Solara Seeks Shareholder Approval for Executive Pay Revisions
Solara Active Pharma Sciences issues a postal ballot notice seeking shareholder approval for revised remuneration packages for its Managing Director and Whole Time Director.
The proposed revisions, ef
Glenmark's IGI Submits IND for ISB 2301 Cancer Drug
Ichnos Glenmark Innovation submitted an IND application to U.S. FDA for ISB 2301, a first-in-class multispecific immune cell activator targeting solid tumors.
The pentaspecific molecule targets three
Bliss GVS Pharma Shareholders Approve Three Director Appointments
Bliss GVS Pharma shareholders approved three director appointments via postal ballot e-voting with over 99.9% votes in favor.
The scrutinizer's report confirmed the voting process complied with SEBI L
ICMR-NIMR Golden Jubilee Marks 80% Malaria Decline
President Murmu inaugurated ICMR-NIMR's Golden Jubilee, highlighting India's 80% decline in malaria cases and deaths between 2015-2025.
India reduced high-burden malaria districts from 155 to 33 and e
Laurus Labs Promoters Sell 2.07 Million Shares
Laurus Labs discloses promoter share sales totaling 2.07 million shares on November 11-12, 2026.
Dr. Satyanarayana Chava sold 1.57 million shares and Mr. V V Ravi Kumar sold 500,000 shares.
The compan
OneSource Specialty Pharma CQO Bernhard Thurnbauer Resigns
Bernhard Thurnbauer resigned as Chief Quality Officer and Senior Management Personnel effective November 17, 2026 due to personal circumstances requiring relocation to Europe.
The resignation was form
Gland Pharma Schedules ADIA One-on-One Investor Meeting
Gland Pharma intimated a one-on-one meeting with Abu Dhabi Investment Authority (ADIA) scheduled for November 20, 2026.
The disclosure is a regulatory filing pursuant to SEBI LODR Regulations, ensurin
India Needs Vigilance to Preserve Polio-Free Status
The press release emphasizes that India’s polio‑free status, achieved through years of vaccination and surveillance, requires ongoing high immunisation coverage.
Wild poliovirus type 1 still circulate
Caplin Steriles US FDA Facility Gets OAI Classification
Caplin Point discloses US FDA classified its subsidiary Caplin Steriles' Gummidipoondi facility as Official Action Indicated (OAI) post-August 2026 inspection.
The company states no material financial
AstraZeneca Pharma India Seeks Shareholder Approval for Independent Director
AstraZeneca Pharma India issues a postal ballot notice seeking shareholder approval for the appointment of Mr. Krishnamurthy Narayanan Iyer as an Independent Director.
The e-voting period for the reso
Hexagon Nutrition Q2 Revenue Grows 15.2% YoY
Hexagon Nutrition reported Q2 FY27 consolidated revenue of ₹1,097 Mn, up 15.2% YoY, with H1 revenue reaching ₹2,140 Mn.
EBITDA for H1 FY27 stood at ₹227 Mn with a 10.6% margin, while PAT was ₹162 Mn w
Symbiotec Pharmalab CIN Changed to L Prefix
Symbiotec Pharmalab Limited changed its Corporate Identification Number (CIN) from U24232MP2002PLC015293 to L24232MP2002PLC015293.
The change reflects the company's listing status as 'Yes' following i
Cipla Faces DRI Search on Import Classification
Cipla discloses a search by the Directorate of Revenue Intelligence at its Mumbai office and Bhiwandi depot on 16 November 2026.
The search was initiated under Section 105 of the Customs Act, 1962, co
Cipla Seeks Shareholder Approval for Rashmi Joshi Director Appointment
Cipla Ltd. issues a postal ballot notice seeking shareholder approval to appoint Ms. Rashmi Joshi as an Independent Director for a five-year term.
The e-voting period is scheduled from 17th November t
Orchid Pharma Q2 FY27 Net Profit Surges 148%
• Orchid Pharma reported standalone Q2 FY27 revenue of ₹341 Cr, a 14% YoY growth, with EBITDA surging 148% to ₹52 Cr.
• The company signed two key EXBLIFEP licensing deals covering Russia and 9 Latin
Natco Pharma November 19 Investec Confluence Meet
Natco Pharma intimates participation in Investec Confluence investor meeting on November 19, 2026, in Pune.
The in-person group meeting is scheduled from 9:00 AM to 2:00 PM and disclosed under SEBI Li
Gufic Biosciences Q2 Earnings Call Audio Upload
Gufic Biosciences uploaded audio recording of Q2 FY27 earnings conference call held on November 16, 2026.
The conference call was conducted at 4:30 PM IST as part of quarterly results disclosure requi
Syngene International Schedules November 20 Investor Meetings
Syngene International intimates BSE and NSE of scheduled one-on-one meetings with analysts and institutional investors on November 20, 2026.
The company confirms no unpublished price sensitive informa
Gland Pharma Allots 3,739 ESOP Equity Shares
Gland Pharma allotted 3,739 equity shares to 2 employees upon exercise of stock options under its 2025 ESOP scheme.
The ESOP Compensation Committee approved the allotment on November 16, 2026, increas
Jubilant Pharmova Q2 Earnings Webinar Upload
Jubilant Pharmova uploaded audio recording of Q2 FY27 earnings webinar per SEBI Regulations 30 and 51.
Webinar covered unaudited standalone and consolidated results for quarter and half-year ended Sep
Veerhealth Care H1FY27 Revenue Up 458% YoY
Veerhealth Care reports H1FY27 standalone unaudited results with ₹47.28 crore revenue, up 458.21% YoY, and ₹2.44 crore PAT, up 397.96% YoY.
Company announces five orders totaling approximately ₹31.3 c
Hexagon Nutrition H1 FY27 Revenue Up 27.3% YoY
Hexagon Nutrition reported H1 FY27 revenue of ₹214.0 crore, up 27.3% YoY, though PAT declined 2.3% to ₹16.2 crore.
EBITDA margin contracted 270 bps to 10.6% in H1 FY27 due to moderated profitability d
Fredun Pharmaceuticals Q2 & H1 FY27 Earnings Call Recording
Fredun Pharmaceuticals submitted audio recording of Q2 & H1 FY27 earnings conference call to BSE.
The earnings call was held on 16th November 2026 discussing un-audited financial results for period en
Gujarat Themis Acquires MicroBioPharm Japan for ₹1,351 Cr
Gujarat Themis Biosyn acquired MicroBioPharm Japan for ₹1,351 crore, expanding into fermentation-based CDMO services with access to Japanese market.
MBJ reported FY26 revenue of ₹557 crore with 25% EB
Kilitch Drugs EGM Unanimously Approves Subsidiary Divestment
Kilitch Drugs EGM approved four resolutions including sale of material subsidiary shareholding and director appointments.
All resolutions passed with near-unanimous shareholder support through remote
TTK Healthcare Board to Consider Bonus Preference Shares
TTK Healthcare's board will meet on November 20, 2026, to approve a scheme for issuing bonus non-convertible redeemable preference shares to equity shareholders.
The trading window for designated pers
FDC Limited ₹120 Crore Tender Offer Buyback
FDC Limited board approved a ₹120 crore tender offer buyback of 24 lakh shares at ₹500 per share, representing a 45.6% premium to recent market prices.
The buyback reserves 15% for small shareholders
Wanbury Clarifies US Market Exposure Unaffected
Wanbury confirms its business and sales remain completely unaffected by a recent undisclosed development.
The company clarifies its US market exposure via the Tanuku facility accounts for just 6% of c
Kilitch Drugs EGM Approves Subsidiary Sale, Debt Conversion
Kilitch Drugs held EGM approving sale of entire stake in material subsidiary and conversion of subsidiary debt to equity.
Meeting approved appointment of Dr. Milind Kishor Madhani and Mr. Gautam Rajan
Kwality Pharma Q2 Revenue Jumps 63% to ₹181 Crore
Kwality Pharma reported Q2 FY27 consolidated revenue of ₹181 crore, a 63% YoY growth, with PAT doubling to ₹29 crore.
The company raised its FY27 revenue guidance to ₹720 crore+ from ₹700 crore, citin
Wanbury Tanuku Plant Receives US FDA OAI Classification
Wanbury received US FDA OAI classification for its Tanuku API plant following a July 2026 inspection.
The company states the OAI status will not impact business continuity or existing customer supplie
Glenmark Launches Authorized Generic Axitinib Tablets
Glenmark Pharmaceuticals Inc., USA launched an authorized generic version of INLYTA® (axitinib) tablets in 1 mg and 5 mg strengths.
The U.S. annual sales for INLYTA® Tablets were approximately $538.4
Biocon Gets U.S. FDA Approval for Pebrilzo Biosimilar
Biocon Limited received U.S. FDA approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Perjeta®, for HER2-positive breast cancer treatment.
The approval strengthens Biocon's oncology portfolio to
Aarti Pharmalabs Chairman Emeritus Chandrakant Gogri Demises
Aarti Pharmalabs announces the demise of Promoter and Chairman Emeritus Shri Chandrakant Vallabhaji Gogri on November 15, 2026.
Shri Gogri was a pivotal figure in the company's growth and development
Aarti Drugs Chairman Emeritus Chandrakant Gogri Demise
Aarti Drugs announces the demise of Promoter and Chairman Emeritus Shri Chandrakant Vallabhaji Gogri on November 15, 2026.
His demise triggers a regulatory reclassification, ceasing his status as a Pr
Anuh Pharma Inaugurates 525 MT/Annum Tarapur Facility
Anuh Pharma inaugurated its new manufacturing facility at Tarapur, Maharashtra on November 15, 2026.
The facility adds 525 MT/annum capacity, increasing total capacity from 2,400 to 2,925 MT/annum.
Th
Anuh Pharma Inaugurates 525 MT/Annum Tarapur Facility
Anuh Pharma inaugurated its new F-10/1 manufacturing facility at Tarapur, Maharashtra on November 15, 2026.
The facility adds 525 MT/Annum capacity, increasing total production capacity to 2,925 MT/An
Themis Medicare Q2 PAT at ₹7.06 Cr vs Loss YoY
Themis Medicare submitted its Q2 & H1 FY27 investor presentation to exchanges, detailing a strong quarterly turnaround.
Q2 FY27 revenue grew 15.1% YoY to ₹89.74 Cr, with API business rebounding 71% an
Gujarat Themis Biosyn Q2 Revenue Up 12% YoY
Gujarat Themis Biosyn reported Q2 FY27 standalone revenue growth of 12.1% YoY to ₹47.5 crore driven by strong volumes and favorable API mix.
EBITDA margins declined to 37.4% due to new fermentation fa
Fischer Medical Ventures Q2 FY27 Results
• Board approved unaudited standalone and consolidated financial results for Q2 and H1 FY27, ending September 30, 2026.
• Standalone net profit surged to ₹2,057.72 lakhs in Q2 from ₹83.77 lakhs YoY, d
Lord's Mark Industries Q2 PAT ₹7,956 Lakh
Lord's Mark Industries submitted revised unaudited financial results for Q2/HY Sep 2026 to correct inadvertent typographical errors in the initial filing.
Standalone PAT for H1 FY27 surged to ₹7,956 l
Parmax Pharma Preferential Issue Funds No Deviation
Parmax Pharma confirms no deviation in utilization of ₹19.28 crore raised via preferential issue of equity shares and warrants.
Funds utilized for working capital requirements (₹6.82 crore) and genera
Parmax Pharma Board Adjourns Q2 Results, Approves Office Shift
Board adjourned approval of un-audited Q2 September 2026 financial results without providing new date.
Approved shifting registered office from Gujarat to Maharashtra, requiring shareholder and regula
ANG Lifesciences Approves Q2 FY26 Results, Appoints Director
ANG Lifesciences board approved unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026.
Appointed Mrs. Preeti Sarin as Additional Independent Director for five-
Jeena Sikho Lifecare Q2 FY27 Financial Results
Jeena Sikho Lifecare Board approved Q2 FY27 standalone and consolidated unaudited financial results for quarter ended September 30, 2026.
Standalone net profit for Q2 stood at ₹36.34 crore on revenue
West Bengal State Dismisses ICHOR Biologics Appeal
Appeal filed by the State of West Bengal against ICHOR Biologics Private Ltd was dismissed for default.
Court observed no appearance by the appellants and no prayer for accommodation was made.
The app
Gufic Biosciences Appoints Dr. Reeta Shah as Independent Director
Gufic Biosciences appointed Dr. Reeta Shah as an Additional Non-Executive Independent Director effective December 1, 2026.
The appointment is for a first term of five years and is subject to sharehold
Panacea Biotec Q2 FY27 Net Profit ₹10.75 Crore
Panacea Biotec reported Q2 standalone net profit of ₹10.75 crore versus loss of ₹15.64 crore YoY, with revenue up 39.5% to ₹126.69 crore.
Consolidated H1 FY27 net profit reached ₹14.11 crore compared
Shree Ganesh Remedies Q2 Earnings Call Recording
Shree Ganesh Remedies submitted audio recording of Q2 FY27 earnings call held on November 14, 2026 to BSE.
The earnings call recording is available via provided web link for investor access and regula
Vaishali Pharma Q2 Net Profit Rises to ₹2.07 Crore
Vaishali Pharma reported unaudited Q2 FY27 standalone revenue of ₹30.17 crore and net profit of ₹2.07 crore.
The board approved Q2 and half-year results ending September 2026, with a clean limited rev
Emcure Cancels JM Financial India Conference Meeting
Emcure Pharmaceuticals cancels its scheduled physical participation in JM Financial's Annual India Conference on November 16, 2026.
The cancellation is due to non-availability of the company's managem
Natural Capsules Corrects Segment Revenue Decimal Error
Natural Capsules issues corrigendum for Q2 FY2027 segment revenue figures due to decimal placement error.
Capsules segment revenue for six months corrected to ₹9,050.16 Lakhs from ₹90,501.62 Lakhs.
AP
Sandu Pharmaceuticals Q2 FY27 Net Profit Rises 121%
Sandu Pharmaceuticals reported unaudited Q2 FY27 net profit of ₹78.57 lakhs, a 121% increase from ₹35.76 lakhs in Q2 FY26.
Half-yearly net profit reached ₹176.61 lakhs with revenue from operations at
Lasa Supergenerics Q2 FY27 Net Loss ₹183.89 Lakhs
Lasa Supergenerics reported Q2 FY27 net loss of ₹183.89 lakhs with revenue collapsing to ₹1.55 lakhs due to complete operational halt.
Company operations remain suspended since May 2025 fire that caus
Bhageria Receives EDQM GMP Inspection Attestation
Bhageria Industries received EDQM GMP attestation for its Vapi facility following a February 2026 inspection.
The approval confirms EU GMP compliance for manufacturing Dexamethasone under CEP No. 2024
Dr. Reddy's USFDA Bachupally Facility Gets VAI Classification
Dr. Reddy's discloses USFDA inspection outcome for its Bachupally formulations facility as 'Voluntary Action Indicated' (VAI).
The USFDA has officially closed the inspection under regulation 21 CFR 20
Orchid Pharma Q2 FY27 Net Profit Rises 444%
Orchid Pharma reported unaudited Q2 FY27 standalone net profit of ₹36.76 crore, a 444% YoY increase, on revenue of ₹341.27 crore.
The board approved financial results for Q2 and H1 FY27, incorporating
Coral Laboratories Q2 FY27 Net Profit Rises 46% YoY
Board approved unaudited standalone financial results for Q2 and H1 FY27, ending September 30, 2026.
Q2 revenue surged 91% YoY to ₹36.37 crore, with net profit up 46% to ₹8.49 crore.
H1 revenue reache
Samrat Pharmachem Q2 Net Profit ₹44.11 Lakh
Board approved Q2 FY27 unaudited standalone results with ₹44.11 lakh profit versus ₹58.71 lakh loss YoY.
Revenue from operations declined to ₹6,600.86 lakh in Q2 from ₹7,887.03 lakh in same quarter la
Desh Rakshak Aushdhalaya Board Approves Materiality Policy
• Desh Rakshak Aushdhalaya Limited's board approved an updated policy for determining materiality of events on November 14, 2026.
• The policy establishes quantitative thresholds based on 2% of turnov
Zydus LiqMeds UK USFDA Inspection Closes with 4 Observations
Zydus Lifesciences discloses closure of USFDA inspection at its UK subsidiary LiqMeds from November 9-13, 2026.
The inspection concluded with 4 observations that the company will address with USFDA ex
Amanta Healthcare Responds to NSE Volume Query
Amanta Healthcare Limited responded to an NSE surveillance query regarding a significant increase in its trading volume.
The company confirmed it has no undisclosed material information or impending c
Dishman Carbogen Q2 Consolidated Loss ₹66.73 Crore
Board approved unaudited standalone and consolidated financial results for Q2 and H1 FY27, reporting consolidated net loss of ₹66.73 crore for the quarter.
Company issued ₹90 crore in secured NCDs via
Natural Capsules Fined ₹10k Each by NSE, BSE
Natural Capsules fined ₹10,000 plus GST by NSE and BSE for insufficient board meeting notice.
Fine resulted from delayed receipt of independent valuation report for preferential issue.
Company paid fi
Rekvina Laboratories Appoints New Company Secretary
Board approved Q2 September 2026 standalone and consolidated unaudited financial results.
Appointed Ms. Bhagyshree Manojbhai Kandoi as Company Secretary and Compliance Officer effective 16 November 20
Eris Lifesciences Reschedules Investor Meet to November 20
Eris Lifesciences postpones its Investor Meet from November 19 to November 20, 2026, due to unavoidable circumstances.
The meeting will be held in Mumbai in both physical and virtual formats for group
Evonile Pharma Shareholders Approve ESOP & Asset Charge
Evonile Pharma shareholders approved two special resolutions via postal ballot, passing both with over 99.78% of votes cast.
Resolution 1 grants employee stock options equal to or exceeding 1% of the
Smruthi Organics Receives Brazilian GMP Certificate
Smruthi Organics received Brazilian GMP Certificate (CBPF) from ANVISA for its Unit II facility in Chincholi, Solapur.
Certificate validates compliance for manufacturing Levanlodipine Besylate Hemipen
Balaxi Pharmaceuticals Nil Physical Share Transfer Re-Lodgement
Balaxi Pharmaceuticals files monthly RTA report on physical share transfer re-lodgement as per SEBI circular.
Report confirms zero requests received, processed, approved, or rejected during October 20
Novelix Reports No Fund Utilisation Deviation
Filed SEBI LODR compliance statement with BSE for no fund utilisation deviation in Q2 FY27.
Raised ₹506.25 lakhs and ₹684.00 lakhs on July 9, 2026, fully utilised as per objects.
Audit committee and b
Aurobindo Pharma Unit Gets US FDA VAI Status
Aurobindo Pharma subsidiary Apitoria Pharma's API Unit 2 received US FDA Establishment Inspection Report with Voluntary Action Indicated classification.
The US FDA inspection was conducted from Septem
IOL Chemicals Clarifies No Undisclosed Volume Impact Events
IOL Chemicals responds to BSE query on significant trading volume increase in its shares.
Company confirms no undisclosed information or events impacting price/volume per SEBI Regulation 30.
Reaffirms
Panacea Biotec October 2026 Zero Shares Dematerialized
Panacea Biotec reported zero shares were dematerialized during the month of October 2026.
The total dematerialized share count remained unchanged at 6,11,09,526 shares as of October 31, 2026.
The disc
Essix Biosciences Acquires 14 Lakh Ind-Swift Shares
Essix Biosciences Ltd, part of the promoter group, acquired 14,00,000 equity shares in Ind-Swift Laboratories Ltd via conversion of fully convertible warrants on October 8, 2026.
The acquisition incre
Panacea Biotec September 2026 Demat Shares Update
Panacea Biotec discloses dematerialization data for September 2026 to BSE and NSE as per SEBI Regulation 74(5).
Total demat shares increased by 1,000 to 6,11,09,526 as of September 30, 2026.
NSDL hold
Nimit Ghatalia Increases Aarey Drugs Stake to 5.18%
Nimit Rajesh Ghatalia disclosed acquisition of 150,000 equity shares in Aarey Drugs & Pharmaceuticals Ltd via warrant conversion.
His shareholding increased to 1,650,000 shares or 5.18% of total capit
Medicamen Biotech Director Sells 32,813 Shares
Medicamen Biotech discloses Director Sanjay Bansal's sale of 32,813 equity shares via on-market transaction.
The transaction, valued at ₹1.05 crore, reduces Bansal's holding from 102,813 shares (0.76%
Bhavna Grover Buys 25,000 Jeena Sikho Shares
Jeena Sikho Lifecare promoter Bhavna Grover purchased 25,000 equity shares via open market on September 29, 2026.
Her personal holding increased from 0.22% to 0.24% of the company's total voting capit
Sanofi India Promoter Group Acquires 15.2% Stake
Sanofi Healthcare India, a promoter group entity, purchased 3.5 million equity shares (15.20% stake) in Sanofi India Limited via a block deal.
The transaction was an inter-se transfer from promoter Ho
Sanofi India Promoter Hoechst Sells 3.5M Shares
Hoechst GmbH, a promoter of Sanofi India, sold 3.5 million equity shares via a block deal on NSE.
The shares were transferred inter-se to Sanofi Healthcare India Private Limited, another promoter grou
Evexia Lifecare Promoter Group Buys 5.03 Million Shares
Shree Saibaba Exim Private Limited, a promoter group entity, acquired 50,33,131 equity shares of Evexia Lifecare Limited via open market purchase on September 23, 2026.
The acquisition increases the p
Essix Biosciences Acquires 70 Lakh Ind-Swift Warrants
Essix Biosciences Ltd acquired 70 lakh convertible warrants in Ind-Swift Laboratories Ltd on a preferential basis on September 17, 2026.
The acquisition increases the promoter & promoter group's total
Shree Saibaba Exim Purchases 3.76M Evexia Lifecare Shares
• Shree Saibaba Exim Private Limited, a Promoter Group entity, purchased 37,61,527 equity shares of Evexia Lifecare Limited on September 18, 2026.
• The acquisition, executed on the open market, incre
Evexia Lifecare Promoter Group Buys 20.7 Lakh Shares
Shree Saibaba Exim Private Limited, a promoter group entity, purchased 20,70,000 equity shares of Evexia Lifecare Limited on September 16, 2026.
The acquisition, executed on the BSE open market, incre
Anupam Rasayan Bliss GVS Open Offer 1,669 Shares Acquired
Anupam Rasayan India Limited's open offer for 26% of Bliss GVS Pharma concluded with only 1,669 shares tendered and accepted, a tiny fraction of the 2.77 crore shares offered.
The acquirer paid ₹299 p
Mihir Shah Acquires 3.77 Lakh Parnax Lab Shares via Gift
Mihir Shah, a promoter of Parnax Lab, acquired 377,355 equity shares from fellow promoter Baiju Shah via inter-se gift transfer on July 21, 2026.
The transaction falls under SEBI Takeover Regulations
Colinz Laboratories Open Offer for 26% at ₹54/share
Saffron Capital issued a reminder advertisement for an open offer by Annjana Dugar, Likhitta Dugar, and Antariksh Dugar with PAC Padam Dugar to acquire 654,966 shares (26%) of Colinz Laboratories at ₹